RNAC
Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.08
−3.03%Year over year
Reported trailing growth
- Revenue
- +44.0%
- EBITDA
- —
- EBIT
- -12.1%
- EPS
- —
- Free cash flow
- -75.6%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -65.3%
- EBITDA
- +23.8%
- EPS
- +30.0%
Three-year CAGR
- Revenue
- -70.7%
- EBITDA
- -79.7%
- EBIT
- -97.5%
- Net income
- -68.3%
- EPS
- -52.6%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026